USFDA completes inspection of Granules India in two facilities

The Vizag facility was inspected by a USFD team from June 26 to 30, while the Jeedimetla facility completed the process from June 19 to 23.

209
USFDA Inspection audit
USFDA Inspection

Last Updated on December 31, 2023 by The Health Master

Granules India Limited, a pharmaceutical company, has completed the U.S. Food and Drug Administration’s (USFDA) Pre-Approval Inspection (PAI) and GMP audit for their facility (Unit IV) at Visakhapatnam in Andhra Pradesh

The company said its facility at Jeedimetla (Hyderabad) also completed the USFDA’s surveillance inspection.

“The Vizag facility was inspected by a USFDA team from June 26 to 30, while the Jeedimetla facility completed the process from June 19 to 23.

The successful completion of the inspection by the FDA reflects our commitment to quality and compliance,” Krishna Prasad Chigurupati, Chairman and Managing Director of Granules India, said.

USFDA completes inspection at Ajanta Pharma with zero observations: Gujarat

USFDA concludes inspection at Zydus with zero observation

USFDA completes inspection of Dr Reddy’s with zero observation

USFDA issues Form 483 with 11 observations IPCA Labs: Ratlam

USFDA issues Form 483 with 4 observations to Aurobindo Pharma

USFDA issues Form 483 with zero observations to Pharma MSMEs: Gujarat

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news